Literature DB >> 10614030

Use of ECT in California, revisited: 1984-1994.

B A Kramer1.   

Abstract

The use of ECT in California was examined from 1984 to 1994 and compared with a previous study examining use from 1977 to 1983. Data were collected from legally required reports submitted to the state for all ECT performed. A total of 28,437 patients (mean = 2585.18 per year) received a total of 160,847 treatments with a mean rate of 0.90 patients/10,000 population. The rate in 1984 (1.15) was similar to the mean rate for 1977-1983 (1.12). The rate dropped in 1986 (0.92) and again in 1991 (0.74). There were 821 patients (2.89% of total) judged to be incapable of giving informed consent who received ECT after a court review. This is similar to the rate of 3% for 1977 to 1983. The number of counties where ECT was available increased from 15 in 1983 to 19 in 1991 and returned to 15 in 1994. The number of facilities providing ECT increased from 62 in 1983 to 83 in 1990 and decreased to 69 in 1994. White patients comprised 91.5% of ECT recipients. Three deaths were reported for a rate of 0.19 deaths/10,000 treatments. Despite its safety and efficacy, the availability of ECT in California continues to remain limited geographically and socioeconomically. The rate of its use has declined. Access to ECT is most limited for public patients. While some of the decline may be related to the introduction of new antidepressants and the rapid expansion of managed care, complex legal regulation bears much of the responsibility.

Entities:  

Mesh:

Year:  1999        PMID: 10614030

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  11 in total

1.  Racial differences in the availability and use of electroconvulsive therapy for recurrent major depression.

Authors:  Brady G Case; David N Bertollo; Eugene M Laska; Carole E Siegel; Joseph A Wanderling; Mark Olfson
Journal:  J Affect Disord       Date:  2011-12-12       Impact factor: 4.839

2.  Contemporary use and practice of electroconvulsive therapy worldwide.

Authors:  Kari Ann Leiknes; Lindy Jarosh-von Schweder; Bjørg Høie
Journal:  Brain Behav       Date:  2012-05       Impact factor: 2.708

3.  ECT in a time of COVID-19.

Authors:  Phern Chern Tor; Adeline H H Phu; Doris S H Koh; Yee Ming Mok
Journal:  J ECT       Date:  2020-03-31       Impact factor: 3.635

4.  Electroconvulsive therapy for treatment of major depression in a 100-year-old patient with severe aortic stenosis: a 5-year follow-up report.

Authors:  John P O'Reardon; Mario A Cristancho; Barbara Ryley; Kajal R Patel; Howard L Haber
Journal:  J ECT       Date:  2011-09       Impact factor: 3.635

Review 5.  Electroconvulsive therapy: Part II: a biopsychosocial perspective.

Authors:  Nancy A Payne; Joan Prudic
Journal:  J Psychiatr Pract       Date:  2009-09       Impact factor: 1.325

6.  Identifying Recipients of Electroconvulsive Therapy: Data From Privately Insured Americans.

Authors:  Samuel T Wilkinson; Edeanya Agbese; Douglas L Leslie; Robert A Rosenheck
Journal:  Psychiatr Serv       Date:  2018-02-01       Impact factor: 3.084

7.  Current clinical practice of electroconvulsive therapy and repetitive transcranial magnetic stimulation in psychiatry, a German sample.

Authors:  Charles Timäus; Jonathan Vogelgsang; Bernhard Kis; Katrin Radenbach; Claus Wolff-Menzler; Kiriaki Mavridou; Stephan Gyßer; Philipp Hessmann; Jens Wiltfang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-01-29       Impact factor: 5.270

8.  Demographics of Patients Receiving Electroconvulsive Therapy Based on State-Mandated Reporting Data.

Authors:  James Luccarelli; Michael E Henry; Thomas H McCoy
Journal:  J ECT       Date:  2020-12       Impact factor: 3.692

9.  An international perspective on the acceptability and sustainability of electroconvulsive therapy.

Authors:  Daniel Maughan; Andrew Molodynski
Journal:  BJPsych Int       Date:  2016-02-01

10.  How bad was unmodified electroconvulsive therapy! A retrospective study.

Authors:  Anindya Kumar Ray
Journal:  Indian J Psychiatry       Date:  2016 Apr-Jun       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.